LifeStance Health Group, Inc. Announces Major Secondary Offering and Share Repurchase

Key Developments:

• 25,000,000 Shares of Common Stock Offered by Selling Stockholders
• Company to Repurchase 7,000,000 Shares Directly from Underwriter
• J.P. Morgan Securities LLC Acts as Sole Underwriter
• Potential Impact on Share Structure and Trading Dynamics

Details of the Offering

LifeStance Health Group, Inc. (“LifeStance” or “the Company”) has entered into an underwriting agreement for a significant secondary offering of its common stock. According to the agreement, certain major stockholders—including TPG VIII Lynnwood Holdings Aggregation, L.P. and multiple Summit Partners entities—are selling a total of 25,000,000 shares of LifeStance common stock (par value \$0.01 per share) through J.P. Morgan Securities LLC, the sole underwriter for this transaction.

Of the 25,000,000 shares being sold:

• 18,000,000 shares are being offered to the public (the “Public Offering Shares”).
• 7,000,000 shares (the “Repurchase Shares”) are being repurchased by LifeStance itself at a price of \$7.01 per share, representing a direct and immediate share buyback.

The public offering price will be determined by the price paid by each investor. There are no free writing prospectuses associated with this transaction.

Major Selling Stockholders

• TPG VIII Lynnwood Holdings Aggregation, L.P. is the largest seller, offering 20,685,061 shares out of its holding of 114,893,244 shares and selling 5,791,817 shares directly to the company for repurchase.
• Summit Partners Growth Equity Fund IX-A, L.P., Summit Investors GE IX/VC IV, LLC, and Summit Investors GE IX/VC IV (UK), L.P. are also participating, though with smaller volumes.

Significance for Shareholders and Market Impact

• Change in Shareholder Base: Large secondary offerings by significant pre-IPO investors like TPG and Summit Partners can be seen as a reduction in their long-term stake, which is often interpreted by the market as a shift in confidence or portfolio rebalancing. However, the fact that the company is simultaneously repurchasing a substantial number of shares may help offset dilution concerns and could be viewed as a sign of management’s confidence in the business.
• Potential for Share Price Volatility: The offering and repurchase are likely to increase short-term trading volumes and may lead to volatility in the share price due to the large block of stock coming to market and the concurrent buyback.
• No Dilutive New Shares: Importantly, these are secondary shares (existing shares held by insiders), so there will be no immediate increase in the total share count outstanding. The repurchase will reduce public float, which can support the share price if investor demand is robust.
• Lock-up and Trading Restrictions: The agreement contains a 90-day lock-up period for the company and participating insiders, restricting further sales or certain types of share transactions, which is designed to provide market stability post-offering.
• Use of Proceeds: Since this is a secondary offering, the company itself does not receive proceeds from the shares sold by the selling stockholders. However, the company is using its own cash to buy back the Repurchase Shares at the offering price.

Financial and Legal Representations

• Financial Health: The company affirms that there has been no material adverse change in its financial position or operations since the period described in the prospectus.
• Compliance: LifeStance asserts compliance with all relevant securities regulations, and the shares being sold are validly issued, fully paid, and non-assessable.
• Risk Factors: The documentation reiterates standard forward-looking statement disclaimers and highlights the absence of any undisclosed material relationships or adverse legal proceedings.

What Investors Should Watch

• Large Insider Sale: Significant insider sales can sometimes be perceived as a bearish signal, depending on the rationale and market’s interpretation.
• Share Repurchase: The concurrent buyback is generally a bullish signal, showing management’s confidence in the company’s valuation.
• Trading Dynamics: The market’s reaction to this combination of insider selling and company share repurchase will depend on demand for the public offering and overall sentiment toward the company.
• Lock-up Expiry: After the 90-day lock-up, additional shares could come to market, which may be a catalyst for further price movement.

Conclusion

This offering and buyback represent a significant event for LifeStance Health Group, Inc., with the potential to impact share price and investor sentiment. Investors should monitor the outcome of the offering, the company’s cash use for repurchase, and ensuing trading activity.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any securities. Investors should consult their own advisors and review the full SEC filings and prospectus before making any investment decisions. Market conditions and company circumstances can change rapidly, and past performance is no guarantee of future results.

View LifeStance Health Group, Inc. Historical chart here